Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Carli

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Neuropharmacology|July 19, 2022
The potent α<sub>2</sub>-adrenoceptor antagonist RS 79948 also inhibits dopamine D<sub>2</sub> -receptors: Comparison with atipamezole and racloprideRoberto Frau, Paola Devoto, Sonia Aroni, et al.
Investigational New Drugs|October 18, 2025
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cellsArianna Bandini, Letizia Biso, Cristina Viaggi, et al.
Sensors (Basel, Switzerland)|July 28, 2022
Virtual Reality for Shoulder Rehabilitation: Accuracy Evaluation of Oculus Quest 2Arianna Carnevale, Ilaria Mannocchi, Mohamed Saifeddine Hadj Sassi, et al.
Pharmaceuticals (Basel, Switzerland)|April 3, 2021
Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical DifferencesMarco Carli, Shivakumar Kolachalam, Biancamaria Longoni, et al.
Current Neuropharmacology|August 20, 2020
Is Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?Marco Carli, Stefano Aringhieri, Shivakumar Kolachalam, et al.
Pharmaceuticals (Basel, Switzerland)|July 29, 2023
A 5-Year Study of Antiseizure Medications (ASMs) Monitoring in Patients with Neuropsychiatric Disorders in an Italian Clinical CenterLetizia Biso, Marco Carli, Shivakumar Kolachalam, et al.
Expert Review of Neurotherapeutics|June 25, 2024
Current nonstimulant medications for adults with attention-deficit/hyperactivity disorderGiulio Emilio Brancati, Anna Magnesa, Donatella Acierno, et al.
Pharmacology & Therapeutics|June 29, 2018
Molecular targets of atypical antipsychotics: From mechanism of action to clinical differencesStefano Aringhieri, Marco Carli, Shivakumar Kolachalam, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|January 13, 2023
Long-term treatment of adult ADHD in a naturalistic setting: Clinical predictors of attrition, medication choice, improvement, and responseGiulio Emilio Brancati, Francesco De Dominicis, Alessandra Petrucci, et al.
Molecular and Cellular Endocrinology|June 5, 2024
Dopamine-mediated autocrine inhibition of insulin secretionEdoardo Ferrero, Matilde Masini, Marco Carli, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Neuropharmacology|July 19, 2022
The potent α<sub>2</sub>-adrenoceptor antagonist RS 79948 also inhibits dopamine D<sub>2</sub> -receptors: Comparison with atipamezole and racloprideRoberto Frau, Paola Devoto, Sonia Aroni, et al.
Investigational New Drugs|October 18, 2025
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cellsArianna Bandini, Letizia Biso, Cristina Viaggi, et al.
Sensors (Basel, Switzerland)|July 28, 2022
Virtual Reality for Shoulder Rehabilitation: Accuracy Evaluation of Oculus Quest 2Arianna Carnevale, Ilaria Mannocchi, Mohamed Saifeddine Hadj Sassi, et al.
Pharmaceuticals (Basel, Switzerland)|April 3, 2021
Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical DifferencesMarco Carli, Shivakumar Kolachalam, Biancamaria Longoni, et al.
Current Neuropharmacology|August 20, 2020
Is Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?Marco Carli, Stefano Aringhieri, Shivakumar Kolachalam, et al.
Pharmaceuticals (Basel, Switzerland)|July 29, 2023
A 5-Year Study of Antiseizure Medications (ASMs) Monitoring in Patients with Neuropsychiatric Disorders in an Italian Clinical CenterLetizia Biso, Marco Carli, Shivakumar Kolachalam, et al.
Expert Review of Neurotherapeutics|June 25, 2024
Current nonstimulant medications for adults with attention-deficit/hyperactivity disorderGiulio Emilio Brancati, Anna Magnesa, Donatella Acierno, et al.
Pharmacology & Therapeutics|June 29, 2018
Molecular targets of atypical antipsychotics: From mechanism of action to clinical differencesStefano Aringhieri, Marco Carli, Shivakumar Kolachalam, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|January 13, 2023
Long-term treatment of adult ADHD in a naturalistic setting: Clinical predictors of attrition, medication choice, improvement, and responseGiulio Emilio Brancati, Francesco De Dominicis, Alessandra Petrucci, et al.
Molecular and Cellular Endocrinology|June 5, 2024
Dopamine-mediated autocrine inhibition of insulin secretionEdoardo Ferrero, Matilde Masini, Marco Carli, et al.
Pageof 6